{"data":[{"accessionNo":"0001213900-26-104066","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-09-18","reportingPerson":"Moringa Partners Ltd","reportingCik":null,"personType":"CO","sharesOwned":1954056,"percentOfClass":17.7,"filedAt":"2026-09-28","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-104066","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-09-18","reportingPerson":"Ilan Levin","reportingCik":"0001849189","personType":"IN","sharesOwned":1954056,"percentOfClass":17.7,"filedAt":"2026-09-28","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-104066","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-09-18","reportingPerson":"Moringa Sponsor, LP","reportingCik":"0001849192","personType":"PN","sharesOwned":1954056,"percentOfClass":17.7,"filedAt":"2026-09-28","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-091845","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-07-30","reportingPerson":"Moringa Sponsor, LP","reportingCik":"0001849192","personType":"PN","sharesOwned":1391790,"percentOfClass":25,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-091845","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-07-30","reportingPerson":"Moringa Partners Ltd","reportingCik":null,"personType":"CO","sharesOwned":1391827,"percentOfClass":10.6,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-091845","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-07-30","reportingPerson":"Ilan Levin","reportingCik":"0001849189","personType":"IN","sharesOwned":1391827,"percentOfClass":10.6,"filedAt":"2026-08-19","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-091333","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary shares, par value $0.135 per share","eventDate":"2026-08-11","reportingPerson":"Mitchell P. Kopin","reportingCik":null,"personType":"HC,IN","sharesOwned":286866,"percentOfClass":4.99,"filedAt":"2026-08-18","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-091333","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary shares, par value $0.135 per share","eventDate":"2026-08-11","reportingPerson":"Daniel B. Asher","reportingCik":null,"personType":"HC,IN","sharesOwned":286866,"percentOfClass":4.99,"filedAt":"2026-08-18","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-091333","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary shares, par value $0.135 per share","eventDate":"2026-08-11","reportingPerson":"Intracoastal Capital LLC","reportingCik":null,"personType":"OO","sharesOwned":286866,"percentOfClass":4.99,"filedAt":"2026-08-18","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-088835","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K114","securityClass":"Ordinary shares, par value $0.135 per share","eventDate":"2026-06-30","reportingPerson":"Mitchell P. Kopin","reportingCik":null,"personType":"HC,IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-088835","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K114","securityClass":"Ordinary shares, par value $0.135 per share","eventDate":"2026-06-30","reportingPerson":"Daniel B. Asher","reportingCik":null,"personType":"HC,IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-088835","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K114","securityClass":"Ordinary shares, par value $0.135 per share","eventDate":"2026-06-30","reportingPerson":"Intracoastal Capital LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-071073","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-06-14","reportingPerson":"Ilan Levin","reportingCik":"0001849189","personType":"IN","sharesOwned":199053,"percentOfClass":10.6,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-071073","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-06-14","reportingPerson":"Moringa Partners Ltd","reportingCik":null,"personType":"CO","sharesOwned":199053,"percentOfClass":10.6,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-071073","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-06-14","reportingPerson":"Moringa Sponsor, LP","reportingCik":"0001849192","personType":"PN","sharesOwned":199053,"percentOfClass":10.6,"filedAt":"2026-06-23","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-062790","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-05-14","reportingPerson":"Moringa Partners Ltd","reportingCik":null,"personType":"CO","sharesOwned":1382346,"percentOfClass":32.99,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-062790","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-05-14","reportingPerson":"Ilan Levin","reportingCik":"0001849189","personType":"IN","sharesOwned":1382346,"percentOfClass":32.99,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-062790","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K130","securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2026-05-14","reportingPerson":"Moringa Sponsor, LP","reportingCik":"0001849192","personType":"PN","sharesOwned":1382346,"percentOfClass":32.99,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0000929638-26-001901","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K122","securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2026-03-31","reportingPerson":"Lind Global Partners III LLC","reportingCik":null,"personType":"PN","sharesOwned":212500,"percentOfClass":4.96,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0000929638-26-001901","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K122","securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2026-03-31","reportingPerson":"EASTON JEFF","reportingCik":null,"personType":"IN","sharesOwned":212500,"percentOfClass":4.96,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0000929638-26-001901","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":"G1281K122","securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2026-03-31","reportingPerson":"Lind Global Fund III LP","reportingCik":null,"personType":"PN","sharesOwned":212500,"percentOfClass":4.96,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-016532","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-12-31","reportingPerson":"Mitchell P. Kopin","reportingCik":null,"personType":"HC,IN","sharesOwned":325000,"percentOfClass":9.4,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-016532","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-12-31","reportingPerson":"Daniel B. Asher","reportingCik":null,"personType":"HC,IN","sharesOwned":325000,"percentOfClass":9.4,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-26-016532","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-12-31","reportingPerson":"Intracoastal Capital LLC","reportingCik":null,"personType":"OO","sharesOwned":325000,"percentOfClass":9.4,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0000929638-25-004297","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-09-30","reportingPerson":"Lind Global Partners III LLC","reportingCik":null,"personType":"PN","sharesOwned":212500,"percentOfClass":6.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0000929638-25-004297","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-09-30","reportingPerson":"Lind Global Fund III LP","reportingCik":null,"personType":"PN","sharesOwned":212500,"percentOfClass":6.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0000929638-25-004297","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-09-30","reportingPerson":"EASTON JEFF","reportingCik":null,"personType":"IN","sharesOwned":212500,"percentOfClass":6.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-25-090412","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2025-09-15","reportingPerson":"Moringa Partners Ltd","reportingCik":null,"personType":"CO","sharesOwned":458824,"percentOfClass":14.67,"filedAt":"2025-09-23","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-25-090412","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2025-09-15","reportingPerson":"Ilan Levin","reportingCik":null,"personType":"IN","sharesOwned":458824,"percentOfClass":14.67,"filedAt":"2025-09-23","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-25-090412","formType":"SCHEDULE 13D/A","amendmentNo":1,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2025-09-15","reportingPerson":"Moringa Sponsor, LP","reportingCik":"0001849192","personType":"PN","sharesOwned":457342,"percentOfClass":14.63,"filedAt":"2025-09-23","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0000929638-25-003514","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-09-12","reportingPerson":"Lind Global Fund III LP","reportingCik":null,"personType":"PN","sharesOwned":224050,"percentOfClass":9.9,"filedAt":"2025-09-18","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0000929638-25-003514","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-09-12","reportingPerson":"Lind Global Partners III LLC","reportingCik":null,"personType":"PN","sharesOwned":224050,"percentOfClass":9.9,"filedAt":"2025-09-18","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0000929638-25-003514","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-09-12","reportingPerson":"EASTON JEFF","reportingCik":null,"personType":"IN","sharesOwned":224050,"percentOfClass":9.9,"filedAt":"2025-09-18","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-25-088637","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-09-11","reportingPerson":"Mitchell P. Kopin","reportingCik":null,"personType":"HC,IN","sharesOwned":244771,"percentOfClass":9.99,"filedAt":"2025-09-17","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-25-088637","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-09-11","reportingPerson":"Daniel B. Asher","reportingCik":null,"personType":"HC,IN","sharesOwned":244771,"percentOfClass":9.99,"filedAt":"2025-09-17","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001213900-25-088637","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary shares, par value $0.0135 per share","eventDate":"2025-09-11","reportingPerson":"INTRACOASTAL CAPITAL, LLC","reportingCik":null,"personType":"OO","sharesOwned":244771,"percentOfClass":9.99,"filedAt":"2025-09-17","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001493152-25-013532","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2025-09-11","reportingPerson":"Orca Capital AG","reportingCik":null,"personType":"CO","sharesOwned":131250,"percentOfClass":6.2,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001493152-25-013429","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp.","ticker":"SLXN","cusip":null,"securityClass":"Ordinary Shares, par value $0.0009 per share","eventDate":"2025-09-12","reportingPerson":"Lincoln Alternative Strategies LLC","reportingCik":null,"personType":"OO","sharesOwned":131250,"percentOfClass":6.18,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"},{"accessionNo":"0001493152-25-013538","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0002022416","issuerName":"Silexion Therapeutics Corp","ticker":"SLXN","cusip":null,"securityClass":"Ordinary Shares, par value $0.0135 per share","eventDate":"2025-09-11","reportingPerson":"Orca Capital AG","reportingCik":null,"personType":"CO","sharesOwned":109432,"percentOfClass":4.9,"filedAt":"2025-09-15","canonicalUrl":"https://xoomar.com/markets/stocks/slxn"}],"updatedAt":"2026-11-04T05:24:55.354Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/slxn","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}